Veru wins US patent allowance for enobosarm-semaglutide weight-loss regimen claims
VERU•Clinical study timeline
Veru is studying enobosarm with semaglutide in older obesity patients; Phase 2b PLATEAU interim DXA analysis is expected in Q1 2027.
Patent allowance covers enobosarm use with semaglutide
Veru received a USPTO notice of allowance for a U.S. patent application covering enobosarm use with semaglutide for “quality” weight loss.
Claims cover dosing regimens during semaglutide therapy, add-on use, or enobosarm monotherapy following semaglutide discontinuation.
Patent term would run to at least Oct. 3, 2044 if issued, before any term adjustments or extensions.
